Phase II trial of carboplatin in advanced malignant melanoma Journal Article
| Authors: | Evans, L. M.; Casper, E. S.; Rosenbluth, R.; Participating Community Clinical Oncology Program Investigators |
| Article Title: | Phase II trial of carboplatin in advanced malignant melanoma |
| Abstract: | Twenty-six evaluable patients with metastatic malignant melanoma who had not received prior chemotherapy were treated in a phase II study with carboplatin (CBDCA), 400 mg/m2 iv every 4 weeks. There were five partial responses of 3, 3+, 5, 7+, and 12+ months' duration. Thrombocytopenia was the dose-limiting toxicity; ten patients had transient platelet count depressions to < 75,000/mm3. Mild to moderate nausea and/or vomiting occurred in 15 patients. Renal, auditory, and neurologic toxic effects were not encountered. Since the response rate of 19% (95% confidence limits, 8%-38%) is similar to that noted for dacarbazine, carboplatin, singly and in combination with other agents, needs further evaluation in patients with malignant melanoma. |
| Keywords: | adult; cancer chemotherapy; clinical article; aged; middle aged; drug efficacy; skin toxicity; carboplatin; melanoma; phase 2 clinical trial; nausea; thrombocytopenia; vomiting; gastrointestinal toxicity; malaise; neoplasm metastasis; blood cell count; drug therapy; alopecia; organoplatinum compounds; adverse drug reaction; therapy; intravenous drug administration; hematologic diseases; drug evaluation; intoxication; humans; human; male; female; priority journal; blood and hemopoietic system |
| Journal Title: | Cancer Treatment Reports |
| Volume: | 71 |
| Issue: | 2 |
| ISSN: | 0361-5960 |
| Publisher: | National Cancer Institute |
| Date Published: | 1987-02-01 |
| Start Page: | 171 |
| End Page: | 172 |
| Language: | English |
| PUBMED: | 3542209 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 5 February 2021 -- Source: Scopus |
